J&J Seeks FDA Nod for Subcutaneous Tremfya as Induction Regimen in UC [Yahoo! Finance]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Yahoo! Finance
Tremfya (guselkumab) in ulcerative colitis (UC) indication, which would provide a more convenient alternative to the current intravenous (IV) therapy. (Source: Johnson & Johnson announced that it has submitted a regulatory filing with the FDA seeking approval for the use of a subcutaneous (SC) induction regimen of its blockbuster immunology medicine Tremfya (guselkumab) in ulcerative colitis (UC) indication.) The SC dose requires less time to administer and is also claimed to be more comfortable compared to an IV dose. (Source: Compared to an IV dose, an SC dose requires less time to administer and is also claimed to be more comfortable.) Tremfya is already approved for plaque psoriasis and active psoriatic arthritis (PsA) indications in several countries, including the United States and Europe. The drug generated sales of $2.7 billion in the first nine months of 2024, up 22% year over year. (Source: Tremfya is already approved for plaque psoriasis and active psoriatic arthritis (
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Sustainability in biopharma: Collaboration and technology light the way forward [Yahoo! Finance]Yahoo! Finance
- Reasons to Retain IART Stock in Your Portfolio for Now [Yahoo! Finance]Yahoo! Finance
- Bending Spoons is taking video platform Brightcove private in $233M acquisition [TechCrunch]TechCrunch
- Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference [Yahoo! Finance]Yahoo! Finance
- Middle East & Africa Ophthalmology Devices Market Forecast to 2031 - Regional Analysis by Product, Application and End User [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 10/15/24 - Beat
JNJ
Sec Filings
- 11/13/24 - Form 13F-HR
- 11/6/24 - Form 25-NSE
- 10/31/24 - Form 4/A
- JNJ's page on the SEC website